Dr. Sadanandam is a Director of the Centre for Global Oncology and a Group Leader in Stratified and Precision Medicine at the Institute of Cancer Research (ICR), London. He is currently applying his multidisciplinary skills to the integrated science of stratified medicine to understand cell-of-origin, inter - and intra-tumoral/immune/stromal heterogeneity, and  test precise therapies for different subtypes of GI cancers. To this point, his team develops and applies primarily AI/ML approaches to integrate large amounts ofomics and clinical data to generate biomarkers and hypotheses to validate further using experimental biology (pre-clinical models) and clinical studies (by profiling clinical samples and developing companion diagnostics). Dr. Sadanandam led/co-led the research to define transcriptome/multi-omics subtypes of pancreatic, colorectalandgastroesophageal cancers associated with prognosis and potentialpersonalisedtherapies (multiple high-impact publications). These subtypes and classifications are highly cited and applied by the clinical research communities. Recently, his team has been hunting for nutrients and metabolism that offer an advantage for cancer cells to grow efficiently and reduce patient prognosis. Hence, blocking such metabolism in cancer cells may be an efficient way to target cancers. Dr. Sadanandam initiated the Centre for Global Oncology at the ICR to enhance cancer research and clinical data orchestration in low-middle income countries (LMIC; including India) and avoid disparity in research. He has been contributing to various consortia and clinical studies, including the Colorectal Cancer Subtyping Consortium,the COLOSSUSConsortium (European Union), and the Indian Cancer Genome Atlas (ICGA) project (Founding Member). He is part of an international multidisciplinary tumour board. He is exploring entrepreneurship opportunities to translate his findings to the clinic in LMIC and high-income countries through a start-up company.